Leadership
CUREVERSE was founded by experts in small molecule drug discovery, brain disease therapeutics, and medicinal chemistry, who united with the shared goal of developing novel treatments for intractable brain disorders.
Small Molecule R&D Professional
Sung Jin Cho
PhD/ Co-Founder
CEO
- Corporate Management
- Execution of non-clinical/clinical trials for lead pipelines and business development
- Ph.D., M.S., and B.S. in Biotechnology, Yonsei University
- Postdoctoral Researcher, Seoul National University, Institute for Basic Science
- Postdoctoral Researcher, Korea Research Institute of Bioscience and Biotechnology (KRIBB)
- Postdoctoral Researcher, University of Illinois Chicago College of Pharmacy
- Postdoctoral Researcher, University of Chicago, Department of Chemistry
- Drug Substance (API) Process Development, SK Biopharmaceuticals
- Lead/Principal Researcher, New Drug Center, KMEDIhub
- Adjunct Professor, Department of Life Sciences, Kyungpook National University
- Secretary-General, Medicinal Chemistry Division, Korean Chemical Society
- Principal Investigator (PI), BIOSTAR Project, KIST
- Key Publications
41 SCI(E) papers in the last 5 years, with 13 as corresponding author.
- Journal of Medicinal Chemistry (JMC): 3 Cover Articles (2016, 2019~2021)
- European Journal of Medicinal Chemistry (EJMC):Papers published in 2016, 2020
- Clinical Cancer Research: Paper published in 2019
- Key Grants
Principal Investigator (PI)
- 2023-2025: National New Drug Development Project (Total ₩1.5 billion / 2 years)
- 2023-2025: Overcoming Dementia R&D Project (Total ₩1.55 billion / 3 years)
- 2021-2024: MSIT BIOSTAR Project (Total ₩1.05 billion / 3 years)
- 2019-2021: MOHW Advanced Biomedical Complex Future Medical Industry One-Stop Support Project (Total ₩3.0 billion / 3 years)
- 2017-2022: MSIT Bio-Medical Technology Development Project (Total ₩0.9 billion / 5 years)
- 2017-2019: Pan-Government Full Cycle New Drug Development Project (Total ₩0.87 billion / 1.5 years)
- 2014-2021: MOHW Leading-edge Diabetes/Metabolic Disease New Drug Development Research Project
- License Out Deal
- 2020: Drug for Refractory Liver Cancer
- 2019: Drug for Acute Pancreatitis (currently in non-clinical development)
- 2016: Drug for Anaplastic Thyroid Cancer
- Awards & Honors
- 2022: Minister of Science and ICT Commendation (Grand Prize for Technology at Special Zone IR Competition)
- 2014: Minister of Health and Welfare Commendation
- 2007: International Postdoctoral Fellowship
- 2006: INVEST Drug Abuse Research Fellowship
